Moderator: Kristian Steen Frederiksen (Copenhagen, Denmark)Guest: Lutz Fröhlich (Mannheim, Germany) The field of dementia and specifically the treatment of Alzheimer´s disease is at the brink of a possible new era in which disease-modifying therapy will become available in the form of anti-bodies directed against beta-amyloid.Prof. Kristian Steen Frederiksen and Prof. Lutz Fröhlich kick off the June episodes on Dementia and Cognitive Disorderswith discussions on the background and development of anti-bodies directed against beta-amyloid development, status with regards to clinical trials in AD of anti-amyloid anti-body therapy, and challenges and opportunities in clinical practice if anti-amyloid anti-body therapy will be approved.